About this trial
The main purpose is to evaluate the accuracy of myocardial imaging obtained through integrated 18F-FDG PET/MR in detecting viable myocardium. The secondary objective is to evaluate whether myocardial imaging obtained through integrated 18F-FDG PET/MR can replace 18F-FDG PET combined with 99mTc MIBI SPECT/CT gated myocardial perfusion imaging.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults under the age of 80
Coronary angiography shows coronary artery disease, with at least 2 coronary arteries having a degree of stenosis greater than 80%
ft ventricular ejection fraction (LVEF)<40%
Acute myocardial infarction onset for at least 3 months
Disqualifiers
1.Patients with diabetes or other patients with poor blood glucose control (fasting blood glucose value on the test day is greater than 10mmol/L) 2.Patients who allergy to MR contrast agent 3.Electronic implants such as pacemakers, nerve stimulators, insulin pumps, cochlear implants 4.Patients who have undergone aneurysm surgery and have intracranial aneurysm clips 5.Patients who have undergone heart surgery and have an artificial heart valve 6.Patients with metal foreign objects in the eyes 7.Patients with metal implants and prostheses, or metal foreign bodies in other parts of body 8.Severe liver and kidney dysfunction 9.Accompanied by arrhythmia such as atrial fibrillation, cerebrovascular disease, and severe pulmonary heart disease 10.Pregnant or plan to pregnant within three months or lactating women 11.Critically ill patients who require the use of life support systems 12.Patients with claustrophobia 13.Other situations which clinical trial personnel deem it inappropriate to participate in this trial
Trial population
Patients who meet the inclusion and exclusion criteria and are willing to follow the research process.
Trial design
Case-control
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Myocardial perfusion tomographic imaging
In accordance with the guidelines established by the American Heart Association, the left ventricular myocardium is segmented into 17 distinct regions and subjected to visual assessment for the identification of reversible myocardial perfusion abnormalities or defects.
Myocardiac metabolic Imaging
In accordance with the guidelines established by the American Heart Association, the left ventricular myocardium is partitioned into 17 segments, which are subsequently assessed for the presence of diminished myocardial FDG uptake.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.